Vijay Bhoj, MD, PhD
Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of PennsylvaniaPerelman School of Medicine at the University of Pennsylvania
Contact Information3400 Civic Ctr Blvd.
8-111 South Pavilion Extension
Philadelphia, PA, 19104
Email: vijay.bhoj@uphs.upenn.edu
Specialty Division
Transfusion Medicine & Therapeutic Pathology
Research Expertise
My research expertise lies in the area of cellular immunotherapy. In particular, I have experience in preclinical development of immunotherapy that employ engineered immuno-receptors (e.g. chimeric antigen receptors) for the treatment of cancer and of non-malignant conditions such as autoimmunity and transplant rejection.
In addition to conducting preclinical in vitro and in vivo studies using animal models, I have experience in conducting correlative studies in patients undergoing immunotherapy to study the immune impact of such therapies.
Clinical Expertise
Transfusion Medicine
Education
B.S. (Biology), The College of New Jersey, 2002
MD University of Texas Southwestern Medical Center, 2010
PhD (Immunology), University of Texas Southwestern Medical Center, 2010
Specialty Certification
American Board of Pathology - Clinical Pathology, 2013
American Board of Pathology - Transfusion Medicine, 2014
Postgraduate Training
Clinical Pathology, Hospital of the University of Pennsylvania, 2010-2013
Clinical Pathology Chief Resident, Hospital of the University of Pennsylvania, 2012-2013
Postdoctoral researcher, The University of Pennsylvania, 2013-2018
Transfusion Medicine, Hospital of the University of Pennsylvania, 2013-2014
Awards and Honors
William Pepper Fellowship
Pathology and Laboratory Medicine
University of Pennsylvania, 2013
Distinguished Young Investigator Award
Immuno-Oncology Young Investigator's Forum, 2015
Gift of Life Award
Ree-Wynn Foundation, 2016
Research Day Poster Award
Children's Hospital of Philadelphia, 2016
Memberships and Professional Organizations
AABB, 2010 - Present
American Society for Apheresis, 2012 - Present
American Society for Hematology, 2016 - present
American Association for Cancer Research, 2016 - Present
Web Links
Selected Publications
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, Asen Bagashev, Derek A Oldridge, Jaclyn Rosenthal, John Van Arnam, Jos J Melenhorst, Diwakar Mohan, Amanda M DiNofia, Minjie Luo, Sindhu Cherian, Jonathan R Fromm 5, Gerald Wertheim, Andrei Thomas-Tikhonenko, Michele Paessler, Carl H June, Eline T Luning Prak, Vijay G Bhoj, Stephan A Grupp, Shannon L Maude, Susan R Rheingold, Blood Advances, 2019, PMID:31738832
The Pharmacology of T Cell Therapies.
Milone Michael C, Bhoj Vijay G, Molecular therapy. Methods & clinical development 8(): 210-221, 2018, PMID:29552577
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Ruella Marco, Xu Jun, Barrett David M, Fraietta Joseph A, Reich Tyler J, Ambrose David E, Klichinsky Michael, Shestova Olga, Patel Prachi R, Kulikovskaya Irina, Nazimuddin Farzana, Bhoj Vijay G, Orlando Elena J, Fry Terry J, Bitter Hans, Maude Shannon L, Levine Bruce L, Nobles Christopher L, Bushman Frederic D, Young Regina M, Scholler John, Gill Saar I, June Carl H, Grupp Stephan A, Lacey Simon F, Melenhorst J Joseph, Nature medicine 24(10): 1499-1503, 2018, PMID:30275568
CAR-T cells (CTL019) for Refractory B-cell Lymphomas
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH, New England Journal of Medicine 377(26): 2545-2554, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster Stephen J, Svoboda Jakub, Chong Elise A, Nasta Sunita D, Mato Anthony R, Anak Özlem, Brogdon Jennifer L, Pruteanu-Malinici Iulian, Bhoj Vijay, Landsburg Daniel, Wasik Mariusz, Levine Bruce L, Lacey Simon F, Melenhorst Jan J, Porter David L, June Carl H, The New England journal of medicine 377(26): 2545-2554, 2017, PMID:29226764
The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network.
Metjian Ara, Tanhehco Yvette C, Aqui Nicole, Bhoj Vijay G, Jamensky Lita, Marques Marisa B, Onwuemene Oluwatoyosi, Pham Huy P, Arepally Gowthami M, Journal of clinical apheresis 31(5): 448-53, 2016, PMID:26575088
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease.
Ellebrecht Christoph T, Bhoj Vijay G, Nace Arben, Choi Eun Jung, Mao Xuming, Cho Michael Jeffrey, Di Zenzo Giovanni, Lanzavecchia Antonio, Seykora John T, Cotsarelis George, Milone Michael C, Payne Aimee S, Science 353(6295): 179-84, 2016, PMID:27365313
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.
Bhoj Vijay G, Arhontoulis Dimitrios, Wertheim Gerald, Capobianchi James, Callahan Colleen A, Ellebrecht Christoph T, Obstfeld Amrom E, Lacey Simon F, Melenhorst Jan J, Nazimuddin Farzana, Hwang Wei-Ting, Maude Shannon L, Wasik Mariusz A, Bagg Adam, Schuster Stephen, Feldman Michael D, Porter David L, Grupp Stephen A, June Carl H, Milone Michael C, Blood 128(3): 360-70, 2016, PMID:27166358
Novel gene and cellular therapy approaches for treating HIV.
Bhoj Vijay G, Thibodeaux Suzanne R, Levine Bruce L, Discovery medicine 21(116): 283-92, 2016, PMID:27232514
Lipoprotein apheresis.
Bhoj Vijay G, Sachais Bruce S, Current atherosclerosis reports 17(7): 39, 2015, PMID:26004920
